The Bio-inflammation Company

Transforming Human Health Through The Restoration Of Ammonia-Oxidizing Bacteria
Learn More

Our Pruritus/Eczema (Itch) Clinical Research Study is Enrolling Now: LEARN MORE

 

An evolutionary approach to restoring health

AOBiome Therapeutics is a clinical-stage therapeutics company addressing a broad range of inflammatory conditions by harnessing a single strain of class defining
Ammonia Oxidizing Bacteria (AOB).

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

Learn More

AOBiome currently has multiple
Phase 2 clinical programs

AOBiome currently has Phase 2 clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea.

 

Learn More

Committed to transforming & improving human health

We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.

Clinical Trials

Clinical Trials

Science

Science

Manufacturing

Manufacturing

About

Pipeline

 

Clinical Trials
Clinical Trials
Science
Science
Manufacturing
Manufacturing
About
About
In the News
August 17, 2021 · Cambridge, MA
AOBiome’s 30 Patient Study Using New Shelf-Stable Formulation of Its Ammonia Oxidizing Bacteria (AOB) Shows Significant Reduction of Itch Levels In Both Pediatric And Adult Subjects Who Suffer From Eczema
Read More
July 17, 2021 · Cambridge, MA
Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome’s B244 Ammonia Oxidizing Bacteria drug therapy
Read More
June 30, 2020 · Cambridge, MA
AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults
Read More